MyMD Pharmaceuticals Files 8-K on Security Holder Rights
Ticker: QCLS · Form: 8-K · Filed: May 23, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Mymd Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | May 23, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $1,000, $1.816, $14 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing, rights
Related Tickers: MYMD
TL;DR
MYMD filed an 8-K on 5/23 for 5/21, changes to security holder rights. Check it out.
AI Summary
MyMD Pharmaceuticals, Inc. filed an 8-K on May 23, 2024, reporting material modifications to security holder rights and other events as of May 21, 2024. The filing also includes amendments to its articles of incorporation or bylaws and financial statements/exhibits. The company was formerly known as Akers Biosciences, Inc.
Why It Matters
This 8-K filing indicates potential changes affecting the rights of MyMD Pharmaceuticals' security holders, which could impact their investment value and voting power.
Risk Assessment
Risk Level: medium — Filings related to modifications of security holder rights and amendments to corporate documents can introduce uncertainty and potential risks for investors.
Key Players & Entities
- MyMD Pharmaceuticals, Inc. (company) — Registrant
- Akers Biosciences, Inc. (company) — Former company name
- May 21, 2024 (date) — Earliest event reported
- May 23, 2024 (date) — Filing date
FAQ
What specific modifications were made to the rights of security holders?
The filing indicates 'Material Modifications to Rights of Security Holders' as an item information, but the specific details of these modifications are not provided in the excerpt.
What amendments were made to the Articles of Incorporation or Bylaws?
The filing lists 'Amendments to Articles of Incorporation or Bylaws' as an item, but the specific changes are not detailed in the provided text.
What is the significance of the 'Other Events' listed in the filing?
The filing notes 'Other Events' as an item, but the nature of these events is not specified in the excerpt.
When was MyMD Pharmaceuticals, Inc. formerly known as Akers Biosciences, Inc.?
The company changed its name from Akers Biosciences, Inc. on April 13, 2017.
What is the primary business of MyMD Pharmaceuticals, Inc. according to its SIC code?
The company's Standard Industrial Classification (SIC) code is 2835, which corresponds to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
Filing Stats: 1,047 words · 4 min read · ~3 pages · Grade level 11.1 · Accepted 2024-05-23 16:05:25
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share MYMD The Nasdaq Capital M
- $1,000 — $0.001 per share and a stated value of $1,000 per share, initially convertible into u
- $1.816 — Common Stock") at a conversion price of $1.816 per share (the "Series G Preferred Stoc
- $14 m — cements for aggregate gross proceeds of $14 million, before deducting fees, commissio
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex3-1.htm (EX-3.1) — 336KB
- ex3-2.htm (EX-3.2) — 391KB
- 0001493152-24-021143.txt ( ) — 1101KB
- mymd-20240521.xsd (EX-101.SCH) — 3KB
- mymd-20240521_lab.xml (EX-101.LAB) — 33KB
- mymd-20240521_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYMD PHARMACEUTICALS, INC. Date: May 23, 2024 By: /s/ Christopher Chapman, M.D. Name: Christopher Chapman, M.D. Title: President and Chief Medical Officer